Medicinal Bioconvergence Research Center | Date: 2014-10-20
An aminopyridine derivative of Formula 1 and a method of preventing or treating cancer using the same. Formula 1: In Formula 1: X1 and X2 are each independently selected from the group consisting of carbon and nitrogen; R1 to R5 are each independently selected from the group consisting of a hydrogen, a straight, a branched, or cyclo alkyl of C1-C4, a halogen, and a hydroxyl; and R6 is a hydrogen or an alkyl of C1-C6.
Medicinal Bioconvergence Research Center | Date: 2014-03-24
Provided is a method of screening for agents for preventing or treating mTORC1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells.
Medicinal Bioconvergence Research Center | Date: 2015-06-01
Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:
Medicinal Bioconvergence Research Center | Date: 2014-04-10
The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.
Medicinal Bioconvergence Research Center | Date: 2014-05-09
The present invention relates to a method for monitoring migration, invasion, and metastasis of cancer cells by observing the shape of cancer cells cultured in a three-dimensional environment and measuring the activity, expression, and changes in expression sites of proteins associated with invadopodia formation and metastasis, and the degradation of an extracellular matrix; and to a method for screening a cancer metastasis inhibitor. More specifically, it was verified that the reduction in c-Jun phosphorylation induced the increase in snail1 and the decrease in cortactin expression in the cells cultured in a three-dimensional environment and the expression regulation relations between the proteins were identical to those in breast cancer tissues obtained from patients. In addition, it was verified that, when breast cancer cells in a three-dimensional collagen gel environment were treated with a JNK inhibitor, the shape of the cells became longer; the contact region of the cells and the extracellular matrix became flattened and thinner; the migration of cancer cells was decreased; and the changes in protein expression was observed, such as the increase in TGF1 expression, the increases in smad2 and smad3 expression and activity, the increase in snail1 expression, the decrease in cortactin expression, and the resulting decrease in invadopodia formation. In addition, in a three-dimensional collagen gel environment, MT1-MMP besides the cortactin can be used as a marker of invadopodia, and it was verified that the inhibition of JNK led to the decrease in cortactin expression and the increase in snail1 expression, badly influenced the site and role of MT1-MMP to inhibit the formation of invadopodia, and inhibited the degrading activity of a collagen gel substrate. Thus, the present invention can be used as a method for monitoring migration, invasion, metastasis, and the degree of metastasis of cancer cells and a method for screening a cancer metastasis inhibitor, and will be useful as one of screening methods capable of creating low-cost, high-efficient added value at the time of pre-clinical tests required for drug development.